Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Generic semaglutide may cut drug prices by 65% in Canada by spring 2026 after patent expiry.
Generic versions of semaglutide, used in drugs like Ozempic and Wegovy, could lower prices by over 65% in Canada as early as spring 2026, following the expiration of Novo Nordisk’s patent on January 4.
Health Canada is reviewing nine generic formulations, with approvals possible within 180 days.
The move could greatly improve access for patients struggling with high costs.
While effective for diabetes and weight management, the drug can cause nausea, vomiting, and diarrhea in about half of users, and weight regain often occurs after stopping.
Experts urge patients to consult healthcare providers before use, especially amid rising concerns about overprescription.
El semaglutido genérico puede reducir los precios de los medicamentos en un 65% en Canadá para la primavera de 2026, después de que expire la patente.